Braveheart Bio, Inc. — Form SCHEDULE 13D
Filed August 14, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Marc Andreessen, Benjamin Horowitz, and affiliated entities (AH Bio Fund IV, L.P., AH 2022 Annual Funds, CLF Partners III) filed a joint Schedule 13D on August 14, 2026, disclosing a beneficial ownership position in Braveheart Bio, Inc. common stock. The filing grants power of attorney to Phil Hathaway and AH Capital Management entities to file future SEC reports. Specific share count, acquisition price, and ownership percentage are not provided in this exhibit-only excerpt.
Why this rating
Powers of attorney and joint filing agreements are administrative boilerplate. Without disclosed ownership %, share count, or acquisition details, cannot assess materiality. Routine VC fund disclosure process.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.